Lilly Competitors and Similar CompaniesClear all
Lilly's competitors and similar companies include Shionogi, Boehringer Ingelheim, Sanofi, Becton, Dickinson and Company, Bristol Myers Squibb, MannKind Corporation, Merck, GSK and Pfizer.
 Lilly Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products. |  Shionogi Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases. |  Boehringer Ingelheim Boehringer Ingelheim International is a pharmaceutical company specializing in animal health, human pharma, and biopharmaceutical contract manufacturing. |  Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Becton, Dickinson and Company Becton, Dickinson and Company (BD) is a company that develops, manufactures, and sells medical supplies, laboratory equipment, and diagnostic products. |  Bristol Myers Squibb Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products. |  MannKind Corporation MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients. |  Merck Merck (also known as MSD) is a company that develops and manufactures medicines and vaccines for human and animal health. |  GSK GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. | |
Founding Date | Founding Date 1876 | Founding Date 1878 | Founding Date 1958 | Founding Date 1994 | Founding Date 1897 | Founding Date 1887 | Founding Date 1991 | Founding Date 1891 | Founding Date 2000 | Founding Date 1849 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||
Locations | Locations Indianapolis, US HQ Buenos Aires, AR Sydney, AU Wien, AT Brussel, BE São Paulo, BR Toronto, CA see more | Locations Osaka, JP HQ Beijing, CN Hong Kong, HK Amagasaki, JP Amagasaki, JP Kanegasaki, JP Misato, JP see more | Locations Ingelheim am Rhein, DE HQ Ouled Fayet, DZ Munro, AR Macquarie Park, AU Wien, AT Minsk, BY Bruxelles, BE see more | Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more | Locations Franklin Lakes, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Wien, AT Aalst, BE Olen, BE see more | Locations Princeton, US HQ Mulgrave, AU Pinewood, AU Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR see more | Locations Westlake Village, US HQ Danbury, US | Locations Rahway, US HQ Munro, AR Macquarie Park, AU Krems An Der Donau, AT Wien, AT Bruxelles, BE Santa Cruz De La Sierra, BO see more | Locations London, GB HQ Boumerdes, DZ Buenos Aires, AR Abbotsford, AU Wien, AT Wavre, BE Rio De Janeiro, BR see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more |
Employees | Employees 47,0009% increase | Employees 4,955 | Employees 1,2338% increase | Employees 82,878 | Employees 72,0003% increase | Employees 34,100 | Employees 39513% increase | Employees 73,0004% increase | Employees 68,629 | Employees 81,0008% decrease |
Valuation ($) | Valuation ($) 903.4 b | Valuation ($) 12.3 b | Valuation ($) N/A | Valuation ($) 141.1 b | Valuation ($) 68.7 b | Valuation ($) 97.8 b | Valuation ($) 1.9 b | Valuation ($) 294.7 b | Valuation ($) 862.5 m | Valuation ($) 163.9 b |
Financial | ||||||||||
Revenue (est.) | Revenue (est.) $65.2b (FY, 2025) | Revenue (est.) ¥499.7b (FY, 2026) | Revenue (est.) €12.7b (FY, 2023) | Revenue (est.) €45.4b (FY, 2025) | Revenue (est.) $21.8b (FY, 2025) | Revenue (est.) $48.2b (FY, 2025) | Revenue (est.) $349m (FY, 2025) | Revenue (est.) $65b (FY, 2025) | Revenue (est.) £32.7b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) |
Cost of goods | Cost of goods $11.1b (FY, 2025) | Cost of goods ¥55.5b (FY, 2026) | Cost of goods €4b (FY, 2023) | Cost of goods €11.6b (FY, 2025) | Cost of goods $11.9b (FY, 2025) | Cost of goods $13.9b (FY, 2025) | Cost of goods $26.8m (FY, 2025) | Cost of goods $16.4b (FY, 2025) | Cost of goods £5.6b (FY, 2025) | Cost of goods $16.1b (FY, 2025) |
Gross profit | Gross profit $54.1b (FY, 2025) | Gross profit ¥491.3b (FY, 2026) | Gross profit €8.7b (FY, 2023) | Gross profit €37.6b (FY, 2025) | Gross profit $9.9b (FY, 2025) | Gross profit $34.3b (FY, 2025) | Gross profit $322.2m (FY, 2025) | Gross profit $48.6b (FY, 2025) | Gross profit £28.5b (FY, 2025) | Gross profit $46.5b (FY, 2025) |
Net income | Net income $20.6b (FY, 2025) | Net income ¥205.9b (FY, 2026) | Net income €5.8b (FY, 2023) | Net income €8b (FY, 2025) | Net income $1.7b (FY, 2025) | Net income $7.1b (FY, 2025) | Net income $5.9m (FY, 2025) | Net income $18.3b (FY, 2025) | Net income £6.3b (FY, 2025) | Net income $7.8b (FY, 2025) |
Operating ⚠ | ||||||||||
Countries | Countries 120 (FY, 2021) | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries 92 (FY, 2021) | Countries 200 (FY, 2024) |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities 4 (FY, 2018) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 8 (FY, 2021) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A |
Phase I Trials Products | Phase I Trials Products 27 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 16 (FY, 2021) | Phase I Trials Products 51 (FY, 2024) |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products 8 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 85 (FY, 2022) | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products 27 (FY, 2024) |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products 10 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 32 (FY, 2022) | Phase III Trials Products 11 (FY, 2021) | Phase III Trials Products 32 (FY, 2024) |
Suppliers | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 68 k (FY, 2019) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 37.5 k (FY, 2021) | Suppliers N/A |
Funding | ||||||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 4.7m | Total funding raised N/A | Total funding raised $ 310m | Total funding raised N/A | Total funding raised $ 15.5m | Total funding raised $ 200m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Shionogi
HQ
Osaka, JP
Employees
4,955
Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases.
View companyBoehringer Ingelheim
HQ
Ingelheim am Rhein, DE
Boehringer Ingelheim International is a pharmaceutical company specializing in animal health, human pharma, and biopharmaceutical contract manufacturing.
View companySanofi
HQ
Paris, FR
Employees
82,878
Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
View companyBecton, Dickinson and Company
HQ
Franklin Lakes, US
Employees
72,000↑ 3% increase
Becton, Dickinson and Company (BD) is a company that develops, manufactures, and sells medical supplies, laboratory equipment, and diagnostic products.
View company